摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

nicotinamide mononucleotide

中文名称
——
中文别名
——
英文名称
nicotinamide mononucleotide
英文别名
NMN;1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-[[hydroxy(oxido)phosphoryl]oxymethyl]oxolan-2-yl]pyridin-1-ium-3-carboximidate
nicotinamide mononucleotide化学式
CAS
——
化学式
C11H14N2O8P
mdl
——
分子量
333.215
InChiKey
DAYLJWODMCOQEW-TURQNECASA-M
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    -3.6
  • 重原子数:
    22
  • 可旋转键数:
    4
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.45
  • 拓扑面积:
    169
  • 氢给体数:
    3
  • 氢受体数:
    8

反应信息

点击查看最新优质反应信息

文献信息

  • Synthesis of nicotinamide adenine dinucleotide (NAD) from adenosine monophosphate (AMP)
    作者:David R. Walt、Victor M. Rios-Mercadillo、Jacques Auge、George M. Whitesides
    DOI:10.1021/ja00546a041
    日期:1980.12
    \D s tar t ing l ronr readi l r ava i lab le AMP (Scheme I ) . Th is sy ,n thes is i a srep roward rh t : deve loprnent o f a pract ica l nonfermentat ion route to NAD and NADP.6 It also i l lustrates the ut i l i t l , of enzymaric methods for the synthesis of useful quanti t ies of complex substances and provides a f lexible route to derivatives ol ' NAD. The key in termediate in th is synthes is
    由于许多这些酶所需的烟酰胺辅因子的消耗,氧化还原酶在有机合成中作为催化剂的接受速度已经放缓。烟酰胺辅因子回收的有效程序允许这些物质就地再生,从而降低了这些物质的有效成本。 3 然而,烟酰胺辅因子在溶液中本质上是不稳定的,4 并且经济优势为任何回收计划获得的收益都是有限的。因此,也有必要开发生产它们的方法,并在使用过程中稳定它们。Herc 我们报告了一种组合的细胞 lfrec 酶和化学合成物是 oi\,\D 启动 ronr readi lr ava i lab le AMP(方案 I)。这是 sy ,n thes 是 ia srep roward rh t :开发用于 NAD 和 NADP 的实用非发酵途径。6 它还说明了酶法合成有用数量的复杂物质的用途,并提供了获得 NAD 衍生物的灵活途径。合成中间体的关键是,烟酰胺单核苷酸 (NMN) 是从 AMP 中分三步制备的。t核糖-5-磷酸(r
  • Metabolic regulation of transcription through compartmentalized NAD <sup>+</sup> biosynthesis
    作者:Keun Woo Ryu、Tulip Nandu、Jiyeon Kim、Sridevi Challa、Ralph J. DeBerardinis、W. Lee Kraus
    DOI:10.1126/science.aan5780
    日期:2018.5.11
    compartmentalized NAD+ synthesis and consumption integrate glucose metabolism and adipogenic (fat-promoting) transcription during adipocyte differentiation (see the Perspective by Trefely and Wellen). Competition between the NAD+ precursors—nuclear NMNAT-1 and cytosolic NMNAT-2—for their common substrate, nicotinamide mononucleotide, regulates the balance between nuclear NAD+ synthesis for adipogenic gene
    整合葡萄糖和脂肪 摄入过多的葡萄糖会使您发胖,但目前尚不清楚这种转化是如何由身体介导的。糖酵解通过处于氧化状态 (NAD+) 的必需辅酶烟酰胺腺嘌呤二核苷酸与基因转录相关联。Ryu 等人。发现分隔的 NAD+ 合成和消耗在脂肪细胞分化过程中整合了葡萄糖代谢和脂肪生成(促进脂肪)转录(参见 Trefely 和 Wellen 的观点)。NAD+ 前体(核 NMNAT-1 和胞质 NMNAT-2)之间竞争共同底物烟酰胺单核苷酸,调节用于脂肪生成基因调控的核 NAD+ 合成与代谢中使用的胞质 NAD+ 合成之间的平衡。科学,这个问题 p。eaan5780; 另见第。603 分隔的 NAD+ 合成整合了细胞代谢和信号依赖性转录程序。引言 烟酰胺腺嘌呤二核苷酸 (NAD) 是一种重要的小分子,参与多种生理和病理过程。氧化形式 NAD+ 作为代谢途径中的辅助因子,以及消耗它的各种酶的底物,例如聚[二磷酸腺苷
  • 制备β-烟酸胺单核苷酸的方法及其应用
    申请人:上海龙翔生物医药开发有限公司
    公开号:CN110483601A
    公开(公告)日:2019-11-22
    本发明属于化学合成领域,具体涉及一种制备β‑烟酰胺单核苷酸的方法及其应用。该制备方法包括:S1、缩合反应:将烟酸乙酯、四乙酰核糖和催化剂在第一溶剂中进行缩合反应得到含有烟酸乙酯三乙酰核苷的溶液;S2、氨解反应:将含有烟酸乙酯三乙酰核苷的溶液经氨气溶液进行氨解反应,得到烟酰胺核苷盐酸盐;S3、磷酸化反应:将烟酰胺核苷盐酸盐与三氯氧磷在第二溶剂中进行反应,得到β‑烟酸胺单核苷酸。该制备方法相比于常规方法,具有操作简单、易放大、易纯化以及收率高等优点。
  • Molecular basis for the inhibition of human NMPRTase, a novel target for anticancer agents
    作者:Javed A Khan、Xiao Tao、Liang Tong
    DOI:10.1038/nsmb1105
    日期:2006.7
    Nicotinamide phosphoribosyltransferase (NMPRTase) has a crucial role in the salvage pathway of NAD+ biosynthesis, and a potent inhibitor of NMPRTase, FK866, can reduce cellular NAD+ levels and induce apoptosis in tumors. We have determined the crystal structures at up to 2.1-Å resolution of human and murine NMPRTase, alone and in complex with the reaction product nicotinamide mononucleotide or the inhibitor FK866. The structures suggest that Asp219 is a determinant of substrate specificity of NMPRTase, which is confirmed by our mutagenesis studies. FK866 is bound in a tunnel at the interface of the NMPRTase dimer, and mutations in this binding site can abolish the inhibition by FK866. Contrary to current knowledge, the structures show that FK866 should compete directly with the nicotinamide substrate. Our structural and biochemical studies provide a starting point for the development of new anticancer agents.
    烟酰胺磷酸核糖基转移酶(NMPRTase)在NAD+生物合成的修复途径中起着关键作用,而NMPRTase的强效抑制剂FK866可以降低细胞中的NAD+水平,并诱导肿瘤细胞凋亡。我们确定了人类和鼠类NMPRTase的晶体结构,分辨率高达2.1Å,包括单独的NMPRTase以及与反应产物烟酰胺单核苷酸或抑制剂FK866的复合物。这些结构表明,Asp219是NMPRTase底物特异性的决定因素,这一点在我们的突变研究中得到证实。FK866结合在NMPRTase二聚体界面上的一个通道中,该结合位点的突变可以消除FK866的抑制作用。与现有知识相反,这些结构表明FK866应该直接与烟酰胺底物竞争。我们的结构和生化研究为开发新的抗癌药物提供了起点。
  • Cloning and Characterization of the NADH Pyrophosphatases from Caenorhabditis elegans and Saccharomyces cerevisiae, Members of a Nudix Hydrolase Subfamily
    作者:WenLian Xu、Christopher A. Dunn、Maurice J. Bessman
    DOI:10.1006/bbrc.2000.2999
    日期:2000.7
    Two genes from Caenorhabditis elegans and Saccharomyces cerevisiae, coding for enzymes homologous to the Nudix hydrolase family of nucleotide pyrophosphatases, have been cloned and expressed in Escherichia coli. The purified enzymes are homodimers of 39.1 and 43. 5 kDa, respectively, are activated by Mg(2+) and Mn(2+), and are 30 to 50 times more active on NADH than on NAD(+). They both have a conserved
    已经克隆了来自秀丽隐杆线虫和酿酒酵母的两个基因,它们编码与核苷酸焦磷酸酶的Nudix水解酶家族同源的酶,并在大肠杆菌中表达。纯化的酶分别为39.1和43. 5 kDa的同型二聚体,被Mg(2+)和Mn(2+)激活,在NADH上的活性比在NAD(+)上高30至50倍。它们均在Nudix盒下游具有保守的氨基酸阵列,首先在大肠杆菌的直向同源酶中可见,其将它们指定为Nudix水解酶的NADH焦磷酸酶亚家族的成员。
查看更多

同类化合物

烟酸单核苷酸 β-烟酰胺单核苷酸 3-氨基甲酰-1-[5-O-(羟基膦酸)-alpha-D-呋喃核糖基]吡啶鎓 but-3-yn-l-yl (((2R,3S,4R,5R)-5-(3-carbamoylpyridin-l-ium-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methyl) phosphate nicotinamide mononucleotide nicotinate D-ribonucleotide 1,4-dihydronicotinamide adenine dinucleotide α-Nicotinamid-mononucleotid 3-Carbamoyl-1-((2S,3S,4R,5S)-3,4-dihydroxy-5-phosphonooxymethyl-tetrahydro-furan-2-yl)-pyridinium NMNH Nicotinamide-benzimidazole dinucleotide [(2R,3S,4R,5R)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl 2-[2-(2-methoxyphenoxy)ethoxy]ethyl phosphate [(2R,3S,4R,5R)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl 2-[1-[5-(naphthalen-1-ylmethylamino)-5-oxopentyl]triazol-4-yl]ethyl phosphate 2-(1-adamantyl)ethyl [(2R,3S,4R,5R)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate 2-[1-[5-(benzhydrylamino)-5-oxopentyl]triazol-4-yl]ethyl [(2R,3S,4R,5R)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate [(2R,3S,4R,5R)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl 2-[2-(3-methylphenoxy)ethoxy]ethyl phosphate [(2R,3S,4R,5R)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl 2-phenylethyl phosphate [(2R,3S,4R,5R)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl 5-phenoxypentyl phosphate [(2R,3S,4R,5R)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl 2-[1-[5-oxo-5-[(4-phenylphenyl)methylamino]pentyl]triazol-4-yl]ethyl phosphate 2-(1-benzyltriazol-4-yl)ethyl [(2R,3S,4R,5R)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate [(2R,3S,4R,5R)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl 2-[2-(3-fluorophenoxy)ethoxy]ethyl phosphate butyl [(2R,3S,4R,5R)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate 1-(3'-deoxy-3'-fluoro-β-D-xylofuranosyl)nicotinamide-5'-phosphate 1-(3'-azido-3'-deoxy-β-D-ribofuranosyl)nicotinamide-5'-(benzyl phosphate) 1-(3'-azido-3'-deoxy-β-D-ribofuranosyl)nicotinamide-5'-(butyl phosphate) [(2R,3S,4R,5R)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl methyl phosphate beta-Nicotinamide mononucleotide [(2R,3S,4R,5R)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl methyl hydrogen phosphate 1-[(2R,3R,4R,5R)-3,4-dihydroxy-5-(phosphonooxymethyl)oxolan-2-yl]pyridin-1-ium-3-carboxylic acid 1-[(2R,3S,4R,5R)-3,4-dihydroxy-5-(phosphonooxymethyl)oxolan-2-yl]pyridin-1-ium-3-carboxylic acid [(2R,3S,4R,5R)-5-(benzimidazol-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl [(2R,3S,4R,5R)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphono phosphate [[(2R,3R,4R,5R)-5-amino-3-hydroxy-4-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2R,3S,4R,5R)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl hydrogen phosphate 1-[(2R,3R,4R,5S)-3,4-dihydroxy-5-(phosphonooxymethyl)oxolan-2-yl]pyridin-1-ium-3-carboxylic acid [(2S,3S,4R,5S)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl dihydrogen phosphate [amino-[5-azanidyl-1-[5-[[[[5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl]oxymethyl]-4-hydroxy-3-phosphonooxyoxolan-2-yl]imidazolidine-4,5-diid-4-yl]methyl]azanide [(2S,3R,4R,5R)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl dihydrogen phosphate 1-[(2S,3S,4R,5S)-3,4-dihydroxy-5-(phosphonooxymethyl)oxolan-2-yl]pyridin-1-ium-3-carboxylic acid Pyridinium, 3-carboxy-1-(5-O-phosphono-beta-D-ribofuranosyl)-, inner salt [(2R,3S,4R,5R)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl [[(2S,3R,4S,5S)-3,4-dihydroxy-5-(4-naphthalen-1-yltriazol-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl] phosphate [(2R,3S,4R,5R)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl [[(2S,3R,4S,5S)-3,4-dihydroxy-5-(4-phenyltriazol-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl] phosphate [[(2R,3S,4R,5R)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2S,3R,4S,5S)-3,4-dihydroxy-5-(4-phenyltriazol-1-yl)oxolan-2-yl]methyl hydrogen phosphate β-nicotinamide mononucleotide [(2R,3R,4S,5R)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl dihydrogen phosphate 1-[(2R,3R,4S,5S)-3,4-dihydroxy-5-(phosphonooxymethyl)oxolan-2-yl]pyridin-1-ium-3-carboxylic acid [(2S,3S,4R,5R)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl dihydrogen phosphate 1-[(2R,3S,4S,5S)-3,4-dihydroxy-5-(phosphonooxymethyl)oxolan-2-yl]pyridin-1-ium-3-carboxylic acid 1-[(2S,3R,4S,5S)-3,4-dihydroxy-5-(phosphonooxymethyl)oxolan-2-yl]pyridin-1-ium-3-carboxylic acid [(2S,3S,4S,5R)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl dihydrogen phosphate [(2S,3S,4S,5S)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl dihydrogen phosphate 1-[(2S,3S,4S,5S)-3,4-dihydroxy-5-(phosphonooxymethyl)oxolan-2-yl]pyridin-1-ium-3-carboxylic acid